High-dose ICS tied to osteoporosis and fracture risk in COPD

Key clinical point: Use of high-dose inhaled corticosteroids (ICS) significantly increased the risk of osteoporosis and fracture in patients with chronic obstructive pulmonary disease (COPD).

Major finding: Patients with COPD using ICS were at an increased risk for any osteoporosis-related event (high dose: risk ratio [RR], 1.52; 95% confidence interval [CI], 1.24-1.82] and low dose: RR, 1.27; 95% CI, 1.13-1.56) compared with those not using ICS.

Study details: The data come from ARCTIC study of 9,651 patients with COPD and 59,454 matched reference controls.

Disclosures: This study was funded by Novartis Pharma AG, Basel, Switzerland. C Janson, K Lisspers, B Ställberg, G Johansson, and K Larsson reported relationships with various pharmaceutical companies, including Novartis. FS Gutzwiller and K Mezzi are employees of Novartis. L Mindeholm is a consultant to Novartis Institutes for Biomedical Research and holds stocks in Novartis. BK Bjerregaard and L Jorgensen are employees of IQVIA and have received remuneration in relation to statistical analyses.

Citation: Janson C et al. Eur Respir J. 2020 Sep 24. doi: 10.1183/13993003.00515-2020.

Key clinical point: Use of high-dose inhaled corticosteroids (ICS) significantly increased the risk of osteoporosis and fracture in patients with chronic obstructive pulmonary disease (COPD).

Major finding: Patients with COPD using ICS were at an increased risk for any osteoporosis-related event (high dose: risk ratio [RR], 1.52; 95% confidence interval [CI], 1.24-1.82] and low dose: RR, 1.27; 95% CI, 1.13-1.56) compared with those not using ICS.

Study details: The data come from ARCTIC study of 9,651 patients with COPD and 59,454 matched reference controls.

Disclosures: This study was funded by Novartis Pharma AG, Basel, Switzerland. C Janson, K Lisspers, B Ställberg, G Johansson, and K Larsson reported relationships with various pharmaceutical companies, including Novartis. FS Gutzwiller and K Mezzi are employees of Novartis. L Mindeholm is a consultant to Novartis Institutes for Biomedical Research and holds stocks in Novartis. BK Bjerregaard and L Jorgensen are employees of IQVIA and have received remuneration in relation to statistical analyses.

Citation: Janson C et al. Eur Respir J. 2020 Sep 24. doi: 10.1183/13993003.00515-2020.

Key clinical point: Use of high-dose inhaled corticosteroids (ICS) significantly increased the risk of osteoporosis and fracture in patients with chronic obstructive pulmonary disease (COPD).

Major finding: Patients with COPD using ICS were at an increased risk for any osteoporosis-related event (high dose: risk ratio [RR], 1.52; 95% confidence interval [CI], 1.24-1.82] and low dose: RR, 1.27; 95% CI, 1.13-1.56) compared with those not using ICS.

Study details: The data come from ARCTIC study of 9,651 patients with COPD and 59,454 matched reference controls.

Disclosures: This study was funded by Novartis Pharma AG, Basel, Switzerland. C Janson, K Lisspers, B Ställberg, G Johansson, and K Larsson reported relationships with various pharmaceutical companies, including Novartis. FS Gutzwiller and K Mezzi are employees of Novartis. L Mindeholm is a consultant to Novartis Institutes for Biomedical Research and holds stocks in Novartis. BK Bjerregaard and L Jorgensen are employees of IQVIA and have received remuneration in relation to statistical analyses.

Citation: Janson C et al. Eur Respir J. 2020 Sep 24. doi: 10.1183/13993003.00515-2020.